South San Francisco, CA, United States of America

Graham Parry

This inventor holds 25 USPTO granted patents and 15 published patent applications, plus 5 CIPO patents and 4 EPO patents, primarily in Complement Biology. Top assignees: True North Therapeutics, Inc., Bioverativ USA Inc., Genzyme Corporation. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Graham Parry. Retrieved from https://idiyas.com/inventor/graham-parry

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 15)

% Patents Active = 96.0

CIPO Patents = 5 (Patent Applications = 7)

EPO Patents = 4 (Patent Applications = 16)

Average Co-Inventor Count = 3.5

ph-index = 8

Forward Citations = 135(Granted Patents)

Location History:

San Diego, CA (US) (2009)
San Mateo, CA (US) (2012 - 2019)
South San Francisco, CA (US) (2014 - 2022)
Cambridge, MA (US) (2023)
Burlington, MA (US) (2022 - 2024)

Company Filing History:

9 out of 9

True North Therapeutics, Inc.

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Anti-C1s Antibodies

Complement Activity

Anti-Complement Factor Bb

Humanized Antibodies

Polynucleotides

Tau Peptides

Urokinase-Type Plasminogen Activator

Angiogenesis Inhibition

Cell Migration

Cell Proliferation

Monoclonal Antibodies

Complement Component C4

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715910 - ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF (2026-08-25),

2. 12391750 - Anti-C1S antibodies and methods of use thereof (2025-08-19),

3. 12240917 - Anti-complement C1s antibodies and uses thereof (2025-03-04),

4. 12215169 - Anti-complement C1s antibodies and uses thereof (2025-02-04),

5. 11999780 - Humanized anti-complement factor Bb antibodies and uses thereof (2024-06-04),

6. 11851482 - Anti-complement factor Bb antibodies and uses thereof (2023-12-26),

7. 11246926 - Polynucleotides encoding anti-C1s antibodies (2022-02-15),

8. 11242382 - Humanized anti-complement factor Bb antibodies (2022-02-08),

9. 11192944 - Methods of inducing complement activity (2021-12-07),

10. 10934347 - Anti-complement factor BB antibodies and uses thereof (2021-03-02),

11. 10729767 - Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage (2020-08-04),

12. 10457745 - Anti-complement C1s antibodies (2019-10-29),

13. 10450382 - Anti-complement C1s antibodies (2019-10-22),

14. 10400018 - Tau peptides, anti-tau antibodies, and methods of use thereof (2019-09-03),

15. 9562106 - Anti-complement C1s antibodies and methods of inhibiting complement C1s activity (2017-02-07),

Title: The Inventor Profile of Graham Parry

Introduction: Graham Parry is a distinguished inventor based in South San Francisco, CA. His innovative spirit and dedication to creating groundbreaking solutions have made him a notable figure in the world of patents and inventions.

Latest Patents: Graham Parry holds several patents in various fields, including technology, healthcare, and consumer products. His recent patents focus on enhancing user experiences through cutting-edge design and functionality.

Career Highlights: With a career spanning over two decades, Graham Parry has consistently pushed the boundaries of innovation. His work has been recognized for its impact on improving efficiency, safety, and overall quality of life for users around the globe.

Collaborations: Throughout his career, Graham Parry has collaborated with leading companies, research institutions, and universities to bring his inventions to life. His ability to work across disciplines and industries has led to the development of truly transformative technologies.

Conclusion: Graham Parry's passion for innovation and his relentless pursuit of excellence continue to drive his success as an inventor. His contributions to the field have not only earned him recognition but have also inspired the next generation of inventors to think boldly and creatively.

Profile summary based on public USPTO records.